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Abstract
Background:  The abnormal accumulation of amyloid-beta peptide is believed to cause
malfunctioning of neurons in the Alzheimer's disease brain. Amyloid-beta exists in different
assembly forms in the aging mammalian brain including monomers, oligomers, and aggregates, and
in senile plaques, fibrils. Recent findings suggest that soluble amyloid-beta oligomers may represent
the primary pathological species in Alzheimer's disease and the most toxic form that impairs
synaptic and thus neuronal function. We previously reported the isolation of a novel amyloid-beta-
degrading enzyme, acyl peptide hydrolase, a serine protease that degrades amyloid-beta, and is
different in structure and activity from other amyloid-beta-degrading enzymes.
Results: Here we report the further characterization of acyl peptide hydrolase activity using mass
spectrometry. Acyl peptide hydrolase cleaves the amyloid-beta peptide at amino acids 13, 14 and
19. In addition, by real-time PCR we found elevated acyl peptide hydrolase expression in brain areas
rich in amyloid plaques suggesting that this enzyme's levels are responsive to increases in amyloid-
beta levels. Lastly, tissue culture experiments using transfected CHO cells expressing APP751
bearing the V717F mutation indicate that acyl peptide hydrolase preferentially degrades dimeric and
trimeric forms of amyloid-beta.
Conclusion: These data suggest that acyl peptide hydrolase is involved in the degradation of
oligomeric amyloid-beta, an activity that, if induced, might present a new tool for therapy aimed at
reducing neurodegeneration in the Alzheimer's brain.
Background
Alzheimer's disease (AD) is a neurodegenerative disorder
resulting from the pathological processing of APP that
leads to the accumulation of amyloid-beta (Aβ) peptide,
neuronal loss, synaptic dysfunction, inappropriate levels
of neurotransmitters, and finally, to irreversible and pro-
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gressive memory loss. Hallmark neuropathological fea-
tures, namely senile plaques and neurofibrillary tangles,
are found in the AD brain [1,2].
Cognitive decline in AD results from progressive dysfunc-
tion of synaptic connections within cortical neuronal
microcircuits. Extracellular plaques were thought to be
responsible for synaptic dysfunction and neuronal loss
based on in vitro studies using synthetic Aβ fibrils which
showed that fibrillar Aβ is toxic to neurons [3-5]. How-
ever, growing evidence suggests that this impairment is
caused by accumulation of non-fibrillar, soluble oligo-
meric forms of the Aβ peptide, a process that triggers early
synaptic disorganization prior to widespread synaptic loss
and neurodegeneration [6]. Thus, soluble Aβ oligomers
and probably the Aβ dimers represent the primary patho-
logical species in AD [7,8]. Although fibrillar amyloid
plaques and soluble Aβ oligomers exist in the brain at the
same time, only a relatively weak correlation was found
between fibrillar plaque density and the degree of demen-
tia [9,10]. Meanwhile, levels of total soluble Aβ, and sol-
uble Aβ oligomers correlated with the degree of synaptic
loss and the severity of cognitive impairment [11,12].
Altered metabolic balance between Aβ generation and Aβ
degradation likely results in Aβ accumulation and in the
change from Aβ monomers to the toxic forms of Aβ oli-
gomers. It is critical, therefore, to find ways to prevent Aβ
oligomer accumulation in order to prevent neuronal tox-
icity and the cascade into neurodegeneration [13].
One way to reduce Aβ oligomer accumulation in the brain
is by increasing the activity of the Aβ-degrading enzymes.
Several proteases were reported as capable of degrading
the Aβ peptide. Neprilysin (NEP) [14], and Insulin
Degrading Enzyme (IDE) [15], were proven to be effective
in vitro and in vivo in decreasing Aβ levels in mice brains.
These proteases are not specific to Aβ, as IDE is known to
affect insulin and beta-endorphin [16], and neprilysin
cleaves a variety of physiologically active peptides such as
substance P, bradykinin, oxytocin, Leu- and Met-
enkephalins, neurotensin, and more [17]. If these
enzymes were to be used as targets for treating AD, they
would need to be activated in a way that selectively
increases their Aβ-degrading activity while minimally
affecting their activity on other substrates [18,19].
We recently purified to homogeneity, as judged by a single
band on a silver stained gel, and identified by mass spec-
trometry, the serine protease acyl peptide hydrolase
(APEH) as an enzyme that degrades Aβ in SKNMC neu-
roblastoma cells [20]. The precise biological activity of
APEH is unknown [21]. APEH is a 75–80 kDa peptidase
and one of four members of the prolyl oligopeptidase
family of serine proteases. APEH degrades peptides
between 30 and 50 amino acids long and preferentially
degrades oxidized peptides [22]. The enzyme is expressed
in heart, liver, kidney, testis, brain, and also found in
erythrocytes, and plasma [21]. Shimizu and colleagues
reported APEH mediated degradation by APEH of oxi-
dized peptides in vitro and demonstrated that APEH activ-
ity was protective to cells under oxidative stress conditions
by clearance of denatured proteins in coordination with
the proteasome system [23,24]. However, other studies,
using APEH isolated from the porcine gastro-intestinal
tract, porcine liver, or from human erythrocytes, describe
APEH as an enzyme that removes acyl groups from N-
acylated peptides [25-27].
We are the first to isolate APEH as an Aβ-degrading
enzyme and here show by mass spectrometry that APEH
cleaves Aβ at amino acids 13, 14 and 19. In addition, we
found elevated APEH expression in brain areas that are
rich in Aβ plaques suggesting that APEH levels are respon-
sive to increases in Aβ levels. Lastly, our results from tissue
culture experiments using transfected CHO cells express-
ing APP751 bearing the V717F mutant indicate that APEH
preferentially degrades dimeric and trimeric Aβ, the most
toxic forms of Aβ shown to affect LTP, and thus memory.
These data indicate that if proven in vivo, APEH may serve
as a new therapeutic target for AD and that induction of
its activity in the brain can lead to prevention or reduction
in Aβ accumulation and Aβ oligomers formation in AD.
Results
APEH cleaves Aβ monomers at three sites
Our previous manuscript [20] described the isolation and
identification of the serine protease acyl peptide hydro-
lase as an enzyme that degrades Aβ. In order to determine
the exact cleavage sites in the Aβ peptide, the APEH
enzyme that was purified from transfected cells was incu-
bated with synthetic Aβ 1–40 for 5 hours. C18 ziptip
desalting was performed followed by direct injection elec-
trospray FTICR mass spectrometry on the resulting pep-
tide fragment mixture. Samples were "freshly" analyzed
every time in order to minimize the loss of hydrophobic
Aβ peptide and its fragments. Figure 1 represents the
results of these experiments on three peptides incubated
simultaneously as described above. Figure 1A shows the
Aβ peptide alone; Figure 1B shows the Aβ peptide incu-
bated with the APEH enzyme, and Figure 1C shows the Aβ
peptide incubated with the APEH enzyme and its specific
inhibitor. The insets in Figures 1A–C show the m/z
regions 522, 567, and 772, corresponding to the [1–13]3+,
[1–14]3+, and [1–19]3+ ion masses. These mass assign-
ments are within 3 ppm of the expected mass as shown in
the table (Figure 1D). Therefore cleavage of Aβ by APEH
occurs after amino acids 13, 14 and 19. While the samples
were reacted with APEH for 5, 8, and 24 hours, the signal
intensities were not consistent except for the 5-hour time
point shown in Figure 1. Thus, these data clearly show the
presence of these fragments, it does not (and can not) say
anything else about the reaction and particularly does notMolecular Neurodegeneration 2009, 4:33 http://www.molecularneurodegeneration.com/content/4/1/33
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Mass spectrometry analysis of soluble Aβ1–40 digested by APEH Figure 1
Mass spectrometry analysis of soluble Aβ1–40 digested by APEH. All three samples were incubated simultaneously for 
5 hours at 37°C. A) The ESI-FTICR mass spectrum of Aβ1–40alone. B) The ESI-FTICR mass spectrum of Aβ1–40 incubated with 
the APEH enzyme. C) The ESI-FTICR mass spectrum of Aβ1–40incubated with both the APEH enzyme and the APEH specific 
inhibitor Ac-Leu-CK. The m/z regions at 522, 567, and 772 are expanded in the insets and correlate within 3 ppm with the cal-
culated masses for the peptide fragment ions [1–13]3+, [1–14]3+, and [1–19]3+ respectively. D) Observed (Exp.) and calculated 
(Theo.) masses of the peaks observed in A-C.Molecular Neurodegeneration 2009, 4:33 http://www.molecularneurodegeneration.com/content/4/1/33
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yield any kinetic data or information about secondary
fragmentation. With such an experiment, it is not possible
to predict, a priori, that the signal intensity of fragments
would increase or decrease monotonically with time
because, in addition to these peptides being generated by
the APEH, the Aβ is slowly being lost to precipitation or
by "sticking" to the side of the tubes resulting in an unde-
tectable amount of fragments left in the tube.
To confirm this result, the same purified enzyme was incu-
bated with iodinated Aβ1–40 peptide and the cleaved
fragments were separated on an acid/urea gel. The autora-
diograph in Figure 2 shows the radioactively labeled frag-
ments resulting from cleavage by APEH. The synthetic Aβ
peptide used in this experiment was iodinated on amino
acid 10 (Tyrosine) therefore only the fragments contain-
ing the iodinated tyrosine are seen on the gel: i.e. the 1–
13, the 1–14 and the 1–19 fragments. In addition, the full
length Aβ peptide band can be seen. These results are
indicative of the cleavages seen by the mass spectrometry
analysis.
APEH transfection reduces the amount of Aβ monomers, 
dimers and trimers in conditioned medium of 7PA2 cells
In order to determine whether APEH can cleave Aβ oli-
gomers, in addition to monomers, we used 7PA2 cells that
secrete oligomeric forms of Aβ into their conditioned
medium [28,29]. Following transfection of 7PA2 cells
with APEH cDNA, serum free conditioned medium was
collected from the cells. Aβ was immunoprecipitated from
the conditioned medium using 6E10 antibodies. Western
blot of Aβ and its fragments with or without APEH over-
expression is shown in figure 3. A clear reduction in both
dimeric and trimeric forms of Aβ is demonstrated in the
cells overexpressing APEH, while there is no difference in
the secreted APPα. The reduction in dimeric and trimeric
Aβ was significant and reproducible, however, there was
variability in the reduction of the monomeric Aβ band
I 125 – Aβ fragments following APEH cleavage Figure 2
I 125 – Aβ fragments following APEH cleavage. Soluble 
Aβ peptide iodinated on amino acid 10 was incubated for 5 
hours with or without purified APEH. Following incubation, 
samples were separated on a 10–20% Tris-tricine gel. The gel 
was then dried and exposed to film. Full length uncut Aβ 
fragment, as well as the cleaved Aβ fragments containing the 
radiolabeled Lys10 are seen on the autoradiograph. Above the 
autoradiograph is the amino acid sequence of the Aβ peptide. 
* denotes iodinated amino acid. Arrows indicate APEH cleav-
age sites.
Levels of Aβ oligomers in conditioned medium of 7PA2 cells  after transfection with APEH Figure 3
Levels of Aβ oligomers in conditioned medium of 
7PA2 cells after transfection with APEH. Serum-free 
conditioned media were collected from 7PA2 cells that were 
non-transfected or transfected with APEH (lanes 3&4). Aβ 
was immunoprecipitated using a mixture of 6E10 and 4G8 
antibodies. Samples were then separated on a 16% Tris-tri-
cine gel and western blot was probed with 6E10 antibodiesA 
Representative gel out of four experiments. Lanes 1) syn-
thetic Aβ 1–40 peptide; 2) Synthetic Aβ 1–42; 3) IP from 
cells not transfected with APEH; 4) IP from cells transfected 
with APEH. Arrows indicate: secreted APP (APP) as well as 
monomers (M), dimers (D) and trimers (T) forms of the Aβ 
peptideB Diagram indicating the average levels of Aβ in the 
presence or absence of APEH from four independent experi-
ments. Values are presented as % of Mock for each Aβ form 
as follows: mock = 100% (n = 4); APEH APP band (n = 2); 
APEH Aβ Trimer (n = 3); APEH Aβ Dimer (n = 3); APEH Aβ 
Mono (n = 4). * Indicates statistically significant p value deter-
mined by T-test.Molecular Neurodegeneration 2009, 4:33 http://www.molecularneurodegeneration.com/content/4/1/33
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between experiments. A representative experiment is
shown in figure 3A. Figure 3B is a graph representing an
average of four independent experiments.
APEH relative expression in brain tissue samples
We previously reported the results of a pilot study done
using real-time PCR on 6 AD and 6 age-matched controls
samples from the frontal lobe [20]. In that previous report
the sample size was small and the difference in APEH
expression was not statistically significant. Here, we
extended our study in order to determine whether there is
a correlation between APEH expression levels and plaque
load in AD brain samples. We performed real-time PCR
experiments on 12 AD and 9 age-matched control brain
samples. For each individual sample we determined the
APEH relative expression in three areas of the brain: the
cerebellum which is known to be low in plaque load in
AD, and the frontal and temporal cortex both of which are
known to be rich in plaques. The results of this study are
described in figure 4 and in table 1. As seen in table 1, on
a scale of 1–8 the plaque load in the cerebellum is
between 0–1 in both AD and controls. On the other hand,
the plaque load in the frontal and temporal cortices of the
AD samples is significantly higher (average 7–8) than the
controls (average 1). As for APEH relative expression, in
the cerebellum we found no significant difference
between AD (average 0.262) and age matched controls
(average 0.125). We also found no significant difference
in APEH relative expression between AD (average 0.35)
and controls (average 0.4) in the frontal cortex. However,
in the temporal cortex the APEH relative expression is sig-
nificantly increased in AD compared to controls (0.55 in
AD vs. 0.2 in controls). Furthermore, APEH relative
expression, in both the frontal and temporal cortices, is
two times higher than that of the cerebellum (0.35–0.4 as
opposed to 0.1–0.2). The results of this study indicate that
more APEH enzyme may be produced in areas where Aβ
levels are higher. This observation fits data reported by
others of lower Aβ levels in cerebellum as compared with
frontal and temporal cortices in AD patients and in ani-
mal models [30,31].
Discussion
Progressive accumulation of the Aβ peptide in brain
regions serving memory and cognition is an early and
invariant feature of Alzheimer's disease [32]. Therefore,
understanding of the mechanism that controls Aβ degra-
dation and finding ways to prevent its accumulation in
the AD brain will serve as an effective therapeutic target
for slowing the progression of the disease. The best stud-
ied enzymes capable of degrading the Aβ peptide, NEP
[14], IDE [15], plasmin [33], and endothelin converting
enzyme (ECE-1) [34] originate from a variety of cell types,
degrade Aβ of various conformational states and in differ-
ent subcellular locations. However, these enzymes have
other substrates in addition to Aβ. We were the first to
describe APEH as an enzyme that degrades Aβ [20]. To
date, no other known biological substrates were reported
for APEH, suggesting that Aβ could be its major substrate
in the brain.
We have previously shown that the Aβ-degrading activity
of APEH is inhibited by APEH specific inhibitors, as well
as by synthetic Aβ peptide in a dose dependent manner
[20]. Using mass spectrometry we show here that APEH
cleaves Aβ at amino acids 13, 14 and 19. We also confirm
this finding by gel electrophoresis of iodinated Aβ, as
shown in figure 2.
As for APEH expression levels, our earlier real-time PCR
data indicated that APEH expression in AD brains is five
times lower than in age-matched controls, but the results
obtained from 6 AD and 6 age-matched control samples
were not statistically significant [20]. However, in this
expanded study that includes a larger number of samples
and three different areas of the brain from each patient,
we show that APEH expression is elevated in brain areas
that are rich in Aβ plaques (figure 4 and table 1). The con-
troversial results could arise from the small number of
samples used in the previous study. Samples from the
temporal and frontal cortices of AD patients showed sim-
ilar amount of plaque load and higher levels of APEH rel-
ative expression as compared with cerebellum samples of
AD, an area known to contain few or no plaques. This
result suggests that APEH levels are responsive to increases
in Aβ levels. In studies examining the Aβ distribution in
different areas of the brain, cerebellum has a low amount
of Aβ and also less amyloid plaques in AD patients com-
pared to temporal and frontal cortices that have the high-
est Aβ levels and the highest number of plaques [30,31].
It seems that APEH levels increase in areas where Aβ levels
increases as a biological response to rid the excess Aβ as
seen in figure 4. Higher APEH levels are seen in both AD
and controls in frontal and temporal cortices compared to
cerebellum, plus a significant increase is observed in tem-
poral cortex of AD compared to controls.
It has been shown in animal models that reduction in
both neprilysin and IDE expression in the brain correlated
with increased Aβ dimers and an increased plaque load.
Furthermore, in mice having both copies of NEP genes
silenced, the loss of function lead to an elevation in the
brain and in plasma of Aβ 40 and 42, prolonged the half
life of soluble Aβ in brain interstitial fluid, and markedly
increased hippocampal amyloid plaque burden [35-37].
Reduction in hippocampal IDE protein levels were
reported and were associated with the APOE-4 allele pres-
ence in the AD patients [38]. Similarly, by western blot
and by PCR experiments using reverse transcriptase, NEP
protein and mRNA levels, respectively, were found to beMolecular Neurodegeneration 2009, 4:33 http://www.molecularneurodegeneration.com/content/4/1/33
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Table 1: Summary of age, gender, PMI and Aβ load in the AD and age-matched controls brain tissues.
Sample Age (years) Gender (M/F) PMI (hrs) Aβ Load
(scale 0–8)
AD CF T
17 4 M N / A 2 8 8
27 2 M 1 8 0 8 8
38 7 M 4 0 4 6
48 3 M 5 0 8 8
58 4 M 2 1 4 4
68 8 M N / A 0 8 8
77 2 M 2 3 8 8
87 9 M 2 3 0 8 8
99 2 M 1 0 0 6 6
10 82 F 4 2 8 8
11 83 F 2 2 7 7
12 85 F 3 0 7 5
Average 81.7 +/- 6.3 7.3 0.8 7 7
Controls
16 7 M 3 0 0 0
27 4 M N / A 0 2 0
38 7 F 2 4 0 3 3
46 2 M N / A 0 0 0
58 9 M 6 0 0 0
68 5 M 4 8 0 4 3
78 7 F 4 0 0 0
87 8 F 6 0 4 3
98 7 M 1 2 0 2 0
Average 79.5 +/- 9.9 14.7 0 1.7 1
Table summarizes the post mortem intervals (PMI) and the Aβ load for each brain tissue specimen used. The plaque counts were performed in 
specific areas using semi-quantitative measures generated using CERAD methodology. They are purely estimates of pathology on a scale of 0–8. 
There was no statistically significant difference in age between groups by T-test. In the AD group, the majority is males since the samples were 
obtained from a VA hospital.
C = Cerebellum; F = Frontal cortex; T = Temporal cortex; Gender: M = Male; F = Female; PMI = post mortem interval.Molecular Neurodegeneration 2009, 4:33 http://www.molecularneurodegeneration.com/content/4/1/33
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lowest in AD patients in the hippocampus and temporal
gyrus, two areas that are vulnerable to senile plaque devel-
opment, and found to be highest in caudate and periph-
eral organs which are resistant to Aβ plaque deposition
[39]. It is possible that the loss of IDE and neprilysin in
AD brain is due to the loss of neurons that produce these
two enzymes or the hypofunction of live neurons as it has
been reported for choline acetyltransferase (ChAT) in AD.
While the upregulation in APEH could come from its
overexpression in astrocytes or microglia, which are
known to be activated both in AD and in brains of animal
models of AD. Once expression of IDE and NEP is
reduced in the AD brain leading to Aβ accumulation,
APEH expression levels in frontal and temporal cortex
may increase in order to remove excess Aβ. The difference
in APEH expression levels between AD and controls are
significant only in the temporal cortex, yet the plaque load
is high in both the frontal and temporal cortex. This result
is consistent with the concept that aggregated Aβ in
plaques may not reflect a direct correlation with APEH as
seen with other measures of pathology or behavior in AD
animal models. Thus, APEH levels may be better corre-
lated with soluble Aβ [20]. In addition, as seen in table 1,
there is a difference in PMI between the AD and control
samples used in the experiment (control PMI being longer
than the AD PMI). This difference may contribute to the
fact that the increasing trend in APEH level between cere-
bellum and the frontal cortex was not statistically signifi-
cant, while the difference in APEH levels between control
and AD in temporal cortex is statistically significant. It is
possible that if there was no difference in PMI between the
AD and control samples, the APEH levels could be more
accurately attributed to difference in levels of Aβ peptide
monomers in these two areas of the brain. As it is clear
from the data presented that aggregated Aβ load (plaque
load) is similar in frontal and temporal cortices despite
the difference in PMI. Therefore we have to assume that
APEH levels are responsive to increase in soluble mono-
meric or oligomeric Aβ levels and this may occur before
the insoluble plaques are formed.
This responsive effect of APEH to increasing Aβ levels
needs to be further elucidated in vivo, in transgenic mice
in order to determine the importance of APEH as an Aβ-
degrading enzyme in vivo.
Lastly, our tissue culture experiments using transfected
CHO cells expressing APP751 bearing the V717F muta-
tion indicate that APEH preferentially degrades dimeric
and trimeric forms of Aβ, the most toxic forms. These oli-
gomers, and specifically the Aβ dimers, were shown to
block LTP in animal models and disrupt memory of
learned behavior in normal rats [8], and thus probably
affect memory in the AD patients. We show here that
7PA2 cells overexpressing APEH have less monomeric,
dimeric and trimeric forms of Aβ in their conditioned
medium. This result indicates that APEH degrades not
only monomers but also soluble dimers and trimers
forms of Aβ oligomers. It is important to note that due to
the fact that no antibodies are available at this time for the
enzyme APEH, the only way we could purify the enzyme
for the purpose of these experiments was by using the
ProBond purification system which yields a very limited
amount of active enzyme from transfected cells. Therefore
it was not possible for us to perform additional experi-
ments using purified enzyme with purified Aβ oligomers,
which could be a more direct proof for such an activity. By
over expressing APEH in the cells we mimic the "in vivo"
Relative expression of APEH in human brain samples Figure 4
Relative expression of APEH in human brain samples. Relative expression of APEH was obtained by Real-Time PCR on 
mRNA from 12 AD and 9 age-matched control brain samples. mRNA was prepared from cerebellum, frontal cortex, and tem-
poral cortex from each individual. APEH quantity was normalized to β-actin in each sample, and the p values were determined 
by student T-test and by Mann-Witney nonparametric rank test.Molecular Neurodegeneration 2009, 4:33 http://www.molecularneurodegeneration.com/content/4/1/33
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conditions. We therefore recognize that these experiments
are not a solid proof that APEH preferably degrades the
oligomers, but the clear difference between the "with/
without" APEH conditions shown, indicate this possibil-
ity. The details of the exact mechanism should be further
investigated and proved by testing the relevance of APEH
in Aβ degradation in mice models by using either APEH
knock-out or overexpressing mice. It is possible that APEH
activity becomes more significant as the Aβ oligomers
start to form. Although APEH is a cytosolic enzyme, it is
also found secreted as we have shown [20] and in this
manuscript. If its role is proven in animal models, APEH
can serve as an important therapeutic target for slowing
the Aβ induced neurodegeneration and dementia in AD.
Conclusion
The findings presented here show that the enzyme APEH
cleaves Aβ at amino acids 13,14 and 19 and that it cleaves
preferentially Aβ dimers and trimers in addition to Aβ
monomers in vitro and in cell culture, respectively. Real-
time PCR data presented here show that APEH levels in
different areas of the brain are responsive to increase in Aβ
levels. We hypothesize that APEH activity increases as
result of the brain response to increasing levels of Aβ in
these areas. In order to prove our hypothesis further exper-
iments in APEH transgenic mice need to be performed. In
vivo experiments will determine the significance of the
Aβ-degrading activity of APEH compared to the other
known Aβ-degrading enzymes such as NEP and IDE
present in these same brain areas as well. If proven in ani-
mals to significantly slow down plaque formation, APEH
can become a new therapeutic target for AD.
Methods
Mass spectrometry experiments and sample preparation
COS 7 cells were transfected with APEH cDNA tagged with
His and V5 and allowed to recover for 24–48 hours prior
to collection of cell lysates. The APEH enzyme was puri-
fied from the transfected cells using the ProBond kit (Inv-
itrogen) under native conditions as described previously
[20]. Samples were separated on NuPAGE gels (Invitro-
gen) and the enzyme activity in 10 μL of each purified
fraction was determined by activity assay on the APEH
specific chromogenic substrate AANA (Bachem), as
described in [20]. All the active fractions that showed a
single APEH band on the silver stained gel, were pooled
together and dialyzed against 50 mM Tris buffer in order
to remove the imidazole that was used to elute the sam-
ples from the Pro-Bond column. Following dialysis, the
pooled fractions were concentrated by filtration through a
Centricon 3 filter (Amicon) and enzyme activity was
assayed again on the AANA substrate. Since the amount of
protein in the purified fractions was below detectable lev-
els by silver staining of gels, we performed all the purifica-
tions under the same conditions, and after concentrating
the sample 4× we used 50 μL of the purified enzyme frac-
tion for mass spectrometry. Fifty micro-liters of purified
enzyme were incubated with 50–100 pmole of freshly dis-
solved (in 50 mM Tris-HCl pH = 7.4) synthetic Aβ1–40
peptide (Bachem) in presence or absence of the APEH
specific inhibitor Ac-Leu-CK. Samples were incubated for
5, 8 or 24 hours at 37°C water bath and immediately fol-
lowing incubation were analyzed by mass spectrometry.
In some experiments (where indicated) synthetic Aβ 1–40
peptide iodinated at position 10 (Tyrosine) was used. The
iodinated Aβ was purchased lyophilized from Peninsula
Laboratories and reconstituted in water immediately
before use.
Mass spectrometry analysis
After C18 ziptip (Millipore) desalting, untreated Aβ (1–
40), Aβ (1–40) incubated with APEH, and Aβ (1–40)
incubated with both APEH and the inhibitor Ac-Leu-CK,
were monitored by electrospray mass spectrometry, using
a custom built ESI-qQq-FTMS [40,41] in direct injection
mode. Figure 1 shows the resulting mass spectra, dis-
cussed below. The spectrum clearly shows the 3+, 4+, and
5+ charge states of the 1–40 as well as a small amount of
a dehydrated 1–39 contaminant. The m/z regions at 521,
567, and 772 are expanded in the insets for comparison.
There is substantial "chemical noise" below m/z  700,
which is due to buffer contaminants in the sample, which
are common in direct injection ESI mass spectra. While
these could, perhaps be removed by HPLC or solid phase
microextraction [42] this approach was avoided due to
potential for loss of the highly hydrophobic Aβ and its
fragments.
Viewing the Aβ cleaved fragments on acid/urea gels
Gradient acid/urea gels (10–20% acrylamide) were pre-
pared and pre run anode to cathode at 250 v for 30 min-
utes at 4°C in 5% glacial acetic acid running buffer.
Samples were prepared with 6× sample buffer containing
80% formic acid, 60% sucrose, and 0.02% methyl green.
Pharmacia protein molecular weight markers, range
2,512–16,949 were dissolved in PBS and 10 μL aliquots
were frozen in -20°C. When needed, each aliquot was
diluted in the 6× sample buffer. Following the pre run,
samples were loaded on the gel and gel was run from
anode to cathode in the cold room (4°C) with increasing
the voltage every 3 minutes as follows: 25 volts, 50, 100,
200 and then 275 volts till the end of the run. The gels
were run until the dye ran off the bottom of the gel. Before
transfer to nitrocellulose the acid/urea gels were neutral-
ized in a washing glass tray with 200 mL of Tris/glycine
transfer buffer on a rocker for 15 minutes. This wash was
repeated for a total of 5 times. After the neutralization
washes, regular western blot gel transfer was performed
for 2.5 hours (100 V) at 4°C. Before probing with anti-
bodies, the MW marker lane was cut out and stained withMolecular Neurodegeneration 2009, 4:33 http://www.molecularneurodegeneration.com/content/4/1/33
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Ponceau S and the markers bands were marked with a pen
before destaining with tap water. The rest of the mem-
brane was boiled in PBS for 5 minutes in a glass dish and
was cooled down in PBS before blocking with 5% milk in
TBST consisting of 20 mM Tris-HCl, 150 mM NaCl, pH =
7.4 containing 1% Triton X-100 for 45–60 minutes. The
membrane was incubated with primary anti Aβ mono-
clonal antibody 6E10 (1:1200 dilution) in 5% milk solu-
tion overnight on a rocker at 4°C. The following day the
membrane was washed 3× with 1% BSA in TBST for 20
minutes each wash, and secondary antibody anti mouse
HRP (1:6000 dilution) was incubated in 2.5% milk in
TBST for 3 hours. After the secondary antibody, mem-
branes were washed 3× for 15 minutes each in TBST, and
placed in ECL solution (Pierce Super Signal West Pico) for
5 minutes prior to development. In some experiments, as
indicated in figure legends, the Aβ fragments were run on
10–20% Tris-tricine gels. The western blots were done as
described above.
Transfection of 7PA2 cells
CHO cells stably transfected with the APP751 cDNA bear-
ing the Val 717 Phe familial AD mutation (referred to as
7PA2 cells) [28,29] were obtained from Dr. D. Selkoe,
Harvard Medical School. The 7PA2 cells were co-trans-
fected with 5 μg of APEH cDNA using lipofectamine (Inv-
itrogen). After transfection cells were allowed to recover
24 hours in growth medium containing 10% FBS. The
next day, the cells were washed with serum free medium
and incubated with 4.5 mL of serum free opti-MEM for 18
hours. The CM was then collected and the Aβ was immu-
noprecipitated (IP) using the 6E10 antibody (1:800 dilu-
tion). Pellets were run on 10–20% Tris-Tricine gels and
transferred to a nitrocellulose membrane. Western blots
were probed with 6E10 antibodies (1:1000) as described
above. The different Aβ forms were detected after ECL
development or autoradiography.
RNA preparation from human brain tissues and real-time 
PCR
Frozen human brain tissues of cerebellum, frontal, and
temporal cortices from each of 12 AD and 9 age-matched
controls were obtained from the Boston University Alzhe-
imer's Disease Center Brain Bank. mRNA was prepared
from each sample using RNeasy (Qiagen) protocol. 2 μg
mRNA from each sample was used for preparation of first
strand cDNA. The detection of APEH relative expression
was measured by real-time PCR as described in [20].
Results were normalized to β-actin. The P values were
determined by student T-test.
Abbreviations
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